Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Wynn Resorts, Limited — how do they compare? Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B), while Wynn Resorts, Limited trades at $90.54 (market cap $9.50B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 14.1× Wynn Resorts, Limited's market cap, and Wynn Resorts, Limited pays a 1.08% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| VRTX | WYNN | |
|---|---|---|
Market Cap | $134.06B | $9.50B |
Sector | Health | Consumer Cyclical |
52-Week High | $557.96 | $133.34 |
52-Week Low | $376.62 | $90.23 |
Enterprise Value | $128.18B | $19.74B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Wynn Resorts (WYNN) trades at $92.22, up 0.74% today, amid mixed technical signals with a bearish moving average trend but neutral oscillators. The company reported Q2 2026 EPS of $1.24, beating expectations, driven by Macau strength, though U.S. margins face pressure. Revenue reached $7.14B in 2025 with a net income margin of 4.58%, while debt remains elevated at $10.5B. Recent institutional buying includes Barrow Hanley's $321M investment, and analysts maintain a bullish consensus price target of $132.44.
Wynn's outlook is supported by Macau recovery and new project pipelines like Wynn Al Marjan, but high capital expenditure and debt load pose risks. The stock offers 44% upside to consensus target, though investors should monitor margin pressures and capex execution. Near-term support lies at $91, with resistance at $93.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
